Challenge 1. Active participation in the patient care process through integration in multidisciplinary teams and care units.HPs actively participate in decision-making regarding the patient's pharmacotherapeutic process through a collaborative and complementary approach, contributing knowledge based on high-quality scientific evidence and on experience with various healthcare professionals who share the same objective of improving health outcomes.

Objectives: To achieve the best clinical and humanistic health outcomes for patients, their environment, and society at large, while improving the quality of the care process, its harmonisation, equity in decision-making, and the efficiency of resource management.

To provide access to high-quality pharmacotherapy to obtain better clinical outcomes in terms of effectiveness, safety, and measures of quality of life, satisfaction, and patient experience.

To foster greater involvement, commitment, and accountability among HPs in the care process, promote a close relationship with patients and the care team, and share structural, functional, and organisational requirements with other healthcare professionals involved.

To increase the visibility of Hospital Pharmacy.

Challenge 2. A culture of continuous education and training as pillars of professional development within HPSs.Training and education activities are implemented, focussing on the needs of the environment (professionals, patients, society), which enable the internalisation of knowledge, techniques, and skills specific to the speciality to ensure excellent quality of healthcare and comprehensive, efficient care.

Objectives: To define a continuous professional development plan based on competencies for HPS professionals, including basic and cross-disciplinary training, tailored to meet the specific job requirements of each pharmacist.

To implement a quality management plan for teaching that incorporates regular assessments of professional knowledge and skills.

Develop the teaching aspect of all HPS professionals, integrating teaching into daily activities.

Challenge 3. Guarantee continuity of pharmaceutical care throughout the care process.Pharmacists specialising in Hospital Pharmacy will provide cross-disciplinary, comprehensive, and integrated PC throughout the patient care process.

Objectives: As an integral part of the care team, the HPS aims to contribute to the effective, safe, and efficient use of medications at each level and area of care that patients occupy, and in their transitions between these areas. This includes providing person-centred pharmaceutical care that is visible, accessible to both patients and professionals, and incorporated into their portfolio of services.

To involve, inform, and educate patients and caregivers in decision-making on issues related to continuity, safety, adherence, appropriateness, and optimal use of medications and other pharmaceutical products to achieve the established therapeutic goals.

To promote and make visible the figure of the "consulting specialty pharmacist" in each healthcare setting, strengthen PC, and establish 2-way communication between patients, carers, and other professionals.

Challenge 4. Therapeutic assessment, positioning, and protocolisation as the basis of pharmaceutical care.HPSs lead the continuous process of drug evaluation, positioning, and protocolisation with the aim of adding value, applying it to clinical pharmaceutical practice, and helping to achieve the best health outcomes and efficiencies that need to be measured and incorporated into the process.

Objectives: To ensure that all HPs utilise drug evaluation in developing protocols and guidelines, and in selecting the best treatment for each patient.

To measure and analyse health outcomes and drug efficiency, including PROM (Patient-Reported Outcome Measures) and data sharing, publishing and incorporating findings into ongoing drug evaluation.

To ensure effective patient-friendly communication related to the evaluation and selection of different treatments.

Challenge 5. Research culture as a driver of change.Research is integrated into professional performance as an essential, continuous, and necessary activity, focussed on outcomes and the improvement of care or teaching processes.

Objectives: To include research in the strategic plan of each HPS, adapted to its characteristics and activities, with defined lines of research and a research roadmap for HPS professionals (doctoral programmes and their continuation).

To strengthen training in basic research methodology and critical reading, database analysis and management tools, and new technologies based on artificial intelligence.

To establish links and partnerships with institutions to facilitate the acquisition of resources (material, human, methodological) and support for the development of research activities.

To involve the public/community in the research projects in which HPSs participate.

Challenge 6. Promote the empowerment and training of PTs.PTs are empowered to conduct tasks delegated by HPs with highest guarantees of quality, safety, and efficiency.

Objectives: To ensure that PTs are co-participants in patient outcomes through their involvement in the tasks assigned to them.

To train and equip PTs across all areas of pharmacy services by specialising and complementing their academic training.

To integrate PTs into the hospital environment, multidisciplinary teams, and with other healthcare professionals.

Challenge 7. The well-being and development of pharmacy professionals.We care for the physical and emotional health of each individual and the team by providing a welcoming environment that cultivates opportunities for personal and professional growth.

Objectives: To promote the implementation of a human resources management policy in HPSs that contributes to the development of horizontal leadership and appropriate planning of individual performance, encourages training and professional development, and ensures the well-being and safety of each individual.

Challenge 8. Incorporate tools to optimise and individualise pharmacotherapy.HPSs integrate knowledge of drug pharmacokinetics and pharmacodynamics with insights derived from recent advances in molecular biology, advanced therapies, and body composition, to guide HPs in therapeutic decision-making, even before treatment begins, with the ultimate goal of achieving better health outcomes for the patient.

Objectives: To assess patients from the clinical point of view, optimise therapeutic and humanistic effects, and minimise toxicity in order to provide individualised care tailored to patient preferences and their environment.

To ensure that HPSs lead the incorporation of tools for optimising and individualising pharmacotherapy in daily healthcare practice.

To optimise processes to achieve more efficient and safer outcomes in relation to the available alternatives, contributing to the sustainability and quality of healthcare.

To strengthen external links with regulatory agencies, universities, and scientific societies, as well as public–private collaboration, among others, including the development of outcome monitoring systems and population-based predictive models based on artificial intelligence and other technologies. This objective aims to democratise knowledge and enhance access to these tools.

Challenge 9. Advancing the digital transformation of Hospital Pharmacy.Digital technologies are dynamically implemented in HPSs to enable the effective improvement of clinical practice patterns and knowledge management, with the aim of delivering value to patients, the healthcare system, and society.

Objectives: To harness the opportunities offered by digital tools to empower patients and provide them with more humanised pharmaceutical care based on their needs and expectations.

To increase the visibility and influence of Hospital Pharmacy for patients, the healthcare system, and society.

To strengthen and promote digital literacy training for both patients and professionals.

To use digital resources to increase safety, effectiveness, and efficiency in the use of medications and medical devices.

To promote digital health research and data analytics to measure health outcomes.

Challenge 10. Lead clinical safety programmes and activities.HPs are leaders and reference specialists in developing and implementing practices focussed on patient safety.

Objectives: To have a clinical safety improvement management plan in place with a particular focus on medication.

To involve patients in aspects related to improving clinical safety.

To ensure that hospital pharmacists are considered the reference experts in clinical safety by patients, healthcare professionals, managers, and health authorities.

Challenge 11. Commitment to healthcare humanisation principles and improving people's experience.Commitment to a care model designed and implemented with the active participation of individuals, bearing in mind their real needs and expectations, while ensuring the application of the humanisation principles of the SEFH.

Objectives: To improve the experience of patients and professionals within the scope of the functions and responsibilities of HPSs.

To include humanisation within the strategic plan of HPSs.

To cultivate an environment that contributes to improving health outcomes.

Challenge 12. Connecting Hospital Pharmacy with patients and the community.Visibility and accessibility of HPs as experts in pharmacotherapy, connecting with the needs of patients and the community.

Objectives: To define the image and develop and strengthen the reputation of HPSs.

To establish communication mechanisms with patients and the community.

To detect patients' needs and expectations and establish adaptive actions and mechanisms to respond to them.

To design and incorporate new solutions to improve patient and citizen access to HPs.

Challenge 13. Strategic links between Hospital Pharmacy and its environment.HPSs develop strategies to generate partnerships and synergies with stakeholders that enable recognition and contribute to the visibility and professional development of HPs as reference specialists in the pharmacotherapeutic process.

Objectives: To define the image and develop and strengthen the reputation of HPSs in the health sector.

To identify the stakeholders, organisations, and people who could be involved in strategic partnerships to promote the development of HPSs, always taking into account the key players.

To develop a strategy for environmental relationships, set clear objectives, establish a roadmap for achieving them, and conduct continuous monitoring.

To expand and strengthen relationships with other healthcare and non-healthcare professionals, both within and outside the hospital ecosystem.

Challenge 14. Prepared for emerging health issues.To lead and promote the activities involved in handling, preparing, and manufacturing medications, medical devices, and research products within any healthcare setting, independently of the pharmaceutical industry. This includes ensuring quality and traceability throughout the product cycle and that of the final product, as well as the safety of patients, caregivers, handlers, and staff administering treatments, while providing them with adequate information. The efficiency of the process and the application of environmental sustainability measures will be optimized.

Objectives: To adhere to the Guide to Good Practices for the Preparation of Medications in HPSs, or any other subsequent document that must be followed. To promote adherence to GMP in those situations where it is required.

To provide information and training to patients and carers, thus ensuring their involvement in the correct use and handling of the medications they use.

To promote research into the handling, preparation, and manufacture of medications and medical devices that support individualised pharmacotherapy and patient access to treatments for clinical situations not covered by the pharmaceutical industry.

To encourage HPSs to handle, prepare, and manufacture medications for third parties.

To increase resources and collaboration for research the compatibility and stability of medications suitable for clinical practice.

Challenge 15. Enhance drug manufacturing and preparation activities.HPSs are prepared to deal with EIDs, to ensure that they can meet the healthcare, teaching, and research needs for which they are responsible when these needs are at risk. To support and collaborate with other stakeholders involved in the development of innovative actions to improve and ensure the pharmacotherapeutic process for patients, adapting to emerging needs as they arise.

Objectives: Facilitate HPs as leaders and reference experts in ensuring the pharmacotherapeutic process of patients under their responsibility during EIDs.

To create an ecosystem to foster the development of innovative solutions that facilitate the functioning of the basic activities of HPSs.

To identify and apply the facilitating elements that can help us in the management of EIDs.

To develop knowledge, competences, and skills that enable us to be prepared to deal with EIDs.

To ensure that HPS professionals have the appropriate resources and tools to provide patient care and protect their own health and safety during EIDS.

To have contingency plans in place.

Challenge 16. Promote corporate social responsibility and align HPS activities with the Sustainable Development Goals.The SEFH and HPSs are aligned and demonstrate their commitment and active participation toward the environment and society as a whole, of which we are a part. As a result, their objectives and activities are aligned with the SDGs of the 2030 agenda, acting in accordance with the ESG (environmental, social, governance) criteria within our sphere of responsibility. It is a priority to work toward achieving climate neutrality and to minimise the environmental impact of professional activities related to Hospital Pharmacy and the use of medications in its area of responsibility.

Objectives: To analyse which SDGs we can influence through our work, in order to contribute to developments that meet current needs without compromising the ability of future generations to meet their needs.

To ensure that HPs act as leaders and are considered reference specialists in all matters relating to the environmental impact of medications and medical devices, waste management, and the promotion of recycling packaging materials where applicable.

To guarantee the rational use of material resources, medical devices, and medications to minimise environmental impact and contribute to climate neutrality, defined as achieving a balance between greenhouse gas emissions and their removal by the planet's natural absorption processes.

To understand the carbon footprint in the value chain of HPS activities, as well as in the use of medications. To include the social perspective inherent to the SDGs and the SEFH Adherence to the Global Compact document, developing it through the activities for which HPSs are responsible.

To ensure the application of governance criteria (integrity, ethics, transparency, etc) in all Hospital Pharmacy processes.

Challenge 17. Leadership in the development, implementation, and monitoring of personalised and advanced therapies.Ensure that HPs have clearly defined responsibilities and actively participate as guarantors of the quality and development of the process, implementation, and monitoring of advanced and personalised therapies.

Objectives: To consolidate HPSs in the processes of the acquisition, reception, storage, custody, preservation, and dispensing of advanced therapies.

To highlight the role of HPs in the traceability of the process in advanced and personalised therapies.

To promote the training of HPs in the production of advanced and personalised therapies.

To participate in the multidisciplinary units where technical and clinical decision-making and outcomes are measured.

To adapt and incorporate the infrastructure and technology needed to develop processes for advanced and personalised therapies.

To consolidate HPs as reference specialists in individualisation and personalisation processes, guided by the global vision of the HPS as a multidisciplinary service.

Challenge 18. Embrace open innovation.Collaborate with different stakeholders in the creation of knowledge flows and strategies to address health challenges by incorporating creative and effective solutions within HPSs and their environment to deliver value to patients and the health system.

Objectives: To promote a cultural change that facilitates the implementation of this collaborative model.

To design and develop a strategy for incorporating the innovation challenges and goals to be achieved.

To include the perspective of the patient in innovation processes.

To create and strengthen internal and external partnerships with industrial, professional, and academic sectors, both public and private.

To participate in external collaborative innovation projects.

To identify sources of funding for implementing innovation.

Challenge 19. Sustainability of the healthcare system.Hospital Pharmacy contributes to the sustainability of the healthcare system by managing resources efficiently and equitably to achieve the best health outcomes, and by seeking improvements to the system that are economically viable in the short and long term. The contribution of Hospital Pharmacy encompasses areas related to medications, medical devices, professional activity, human resources, and other relevant domains. It has sufficient perspective to collaborate within and outside HPSs, including organising the activities of other healthcare professionals, improving public health and the healthcare environment. This activity involves the continuous evaluation of contributions, including their economic impact and health outcomes.

Objectives: To raise awareness of the importance of sustainability among all HPS professionals.

To estimate economic impacts on health outcomes and the environment before implementing any action or change in the health system (interventions, treatments, measures, processes).

To continuously evaluate any action or change in the health system, allowing for modifications based on the outcomes.

To encourage Hospital Pharmacy professionals, the public, other healthcare professionals, and managers in the healthcare environment to recognise their responsibility for the sustainability of the healthcare system.

Challenge 20. Indication and appropriateness of pharmacotherapy.HPs participate in determining the indication and appropriateness of pharmacological treatments under established and authorised conditions and requirements, and take responsibility for the health outcomes resulting from this practice. The goal is to improve the effectiveness, safety, efficiency, and convenience for patients and the health system, while also taking into account environmental, social, and governance sustainability criteria.

Objectives: To define processes for determining the indication and appropriateness of pharmacotherapy that HPSs intend to include in their portfolio of services for which they have specifically trained professionals.

To identify the therapeutic areas and procedures for determining the indication and appropriateness of pharmacotherapy, and to approve the necessary protocols through the relevant committees.

To record and measure the activities of pharmacists in determining indications and appropriateness, and to assess their value in terms of health outcomes and systemic efficiency.

To advance specific training in the determination of pharmacotherapeutic indications and appropriateness.